PERSONAL INFORMATION
Name: Ma Yongping
Gender: male
Title: professor
Position: PI
CONTACT INFORMATION
Email: ypma99@163.com
Address: Chongqing Medical University，
Yuzhong District, Yi XueYuan Road, No. 1
Chongqing, 400016, China
Phone: +86-23-68485991
EDUCATION EXPERIENCE
1986-1989 Graduated from Biology department, Tianshui Teachers College.
1995-1997 Graduated from Gansu Education College, majoring in English in 1997.
1997-2000 Graduated from Biology department, Wuhan University and received a master's degree.
2003-2005 Graduated from clinical diagnostics department, Chongqing Medical University and received a Ph. D degree.
WORKING EXPERIENCE
Dr. Ma worked in Chongqing Medical University since 2000. He’s a member of The Chinese Society of Biochemistry and Molecular Biology (CSBMB) and the faculty of Chongqing Division of CSBMB. A member of The Chinese Society of Cell Biology (CSCB), He worked in National Institutes of Health of NIAID (NIH/NIAID) in USA as a visiting scientist from 2009 to 2010.
RESEARCH INTERESTS
In recent year, Dr. Ma focused on the genetic modified oral subunit vaccine development and the targeting gene-therapy of solid cancer and got some important success. He has got four funding programs from the National Natural Science Foundation of NSFC (No.30200244; No.30410403264; No.30671865; No.30972585) and two funding programs from local government (No. CSTC2011BB5125; 2021B030301015-2) since 2003. In addition, He authorized six national invention patents and published about seventy academic articles.
HONOUR & AWARDS
In 2004, Dr. Ma was entitled “The first Middle-aged Backbone Teacher of colleges and universities in Chongqing City.”
In 2006, he was selected “an auxiliary of technological expertise and academic leaders in Chongqing City.”
PUBLICATIONS
[1] Wang Casen Y, Ma Y*. Bifidobacterium infantis-Mediated Herpes Simplex Virus-TK/Ganciclovir Treatment Inhibits Cancer Metastasis in Mouse Model. Int J Mol Sci. 24(14):11721. 2023
[2] Fang C, Ma Y*. Peripheral Blood Genes Crosstalk between COVID-19 and Sepsis. Int J Mol Sci. 2023 Jan 30;24(3):2591. doi: 10.3390/ijms24032591.
[3] Jiang Min, Fang C, Ma Y*. Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Gastric Cancer. biomolecules. 2023 March 3; 13(3): 469. doi: 10.3390/ biom13030469.
[4] Xuhuai Fu, Xinmin Li, Daobin Han, Wei Yang, Changjin Liu, Lu Fan, Shijia Ding, Yongping Ma. Ultrasensitive electrochemical biosensor for des-gamma-carboxy prothrombin analysis based on core-shell Pd@PtCu-alloy loaded on WS2 nanosheet.Journal of Electroanalytical Chemistry. 888 (2021) 115213. DOI：10.1016/j.jelechem.2021.115213
[5] Liu L, Ma Y, Zhou H, Wu M. Quantitative Proteomic Analysis of Escherichia coli Heat-Labile Toxin B Subunit (LTB) with Enterovirus 71 (EV71) Subunit VP1. Int J Mol Sci. 2016 Aug 27;17(9). pii: E1419. doi: 10.3390/ijms17091419. PubMed PMID:27618897; PubMed Central PMCID: PMC5037698.
[6] Wang C, Ma Y, Hu Q, Xie T, Wu J, Zeng F, Song F. Bifidobacterial recombinant thymidine kinase-ganciclovir gene therapy system induces FasL and TNFR2 mediated antitumor apoptosis in solid tumors. BMC Cancer. 2016 Jul 27;16:545. doi:10.1186/s12885-016-2608-3. PubMed PMID: 27464624; PubMed Central PMCID:PMC4964087.
[7] Zhou H, He Z, Wang C, Xie T, Liu L, Liu C, Song F, Ma Y. Intravenous
Administration Is an Effective and Safe Route for Cancer Gene Therapy Using the Bifidobacterium-Mediated Recombinant HSV-1 Thymidine Kinase and Ganciclovir. Int J Mol Sci. 2016 Jun 6;17(6). pii: E891. doi: 10.3390/ijms17060891. PubMed PMID:27275821; PubMed Central PMCID: PMC4926425.
[8] Ma Y. Recent advances in nontoxic Escherichia coli heat-labile toxin and its derivative adjuvants. Expert Rev Vaccines. 2016 Nov;15(11):1361-1371. PubMed PMID: 27118519.
[9] Ma Y. Identification of G and P genotype-specific motifs in the predicted VP7 and VP4 amino acid sequences. Virus Res. 2015 Dec 2;210:271-8. doi:10.1016/j.virusres.2015.08.021. PubMed PMID: 26321159.
[10] Ma Y, Wen X, Hoshino Y, Yuan L. Cloning and nucleotide sequence analyses of 11 genome segments of two American and one British equine rotavirus strains. Vet Microbiol. 2015 Mar 23;176(1-2):172-8. doi: 10.1016/j.vetmic.2015.01.008. PubMed PMID: 25631250; PubMed Central PMCID: PMC4329044.
[11] Ma Y, Xie TT, Hu Q, Qiu Z, Song F. Sequencing analysis and characterization of the plasmid pBIF10 isolated from Bifidobacterium longum. Can J Microbiol. 2015 Feb;61(2):124-30. doi: 10.1139/cjm-2014-0581. PubMed PMID: 25587774.
[12] Hu Q, Qiao Y, Nie X, Cheng X, Ma Y. Bevacizumab in the treatment of pterygium:a meta-analysis. Cornea. 2014 Feb;33(2):154-60. doi:10.1097/ICO.0000000000000037. PubMed PMID: 24326333.
[13] Ma Y, Luo Y, Huang X, Song F, Liu G. Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli. Microbiology. 2012 Feb;158(Pt 2):498-504. doi: 10.1099/mic.0.049932-0. PubMed PMID: 22053005.
[14]Tang W, He Y, Zhou S, Ma Y, Liu G. A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer. J Exp Clin Cancer Res. 2009 Dec 16;28:155. doi:10.1186/1756-9966-28-155. PubMed PMID: 20015348; PubMed Central PMCID:PMC2803447.
[15] Peng Y, Ma Y, Xia Y, Qiu Z. Bioinformatics analysis conditions optimization by Peptide Mass Fingerprint identify proteins. Chinese J Anal Chem. 2008; 36(4): 467-72.
[16] Peng Y, Ding S, Ma Y, Xia Y, Qiu Z. Effect of MALDI-TOF-MS analysis conditions and accuracy rating on protein database search on Peptide Mass Fingerprint identifies proteins. Chinese J Anal Chem. 2009; 37(3): 319-24. [17] Ruyue Luo, Sijie Gan and Yongping MA*. Polymerase Chain Reaction Can Run Faster by Parameter Optimization, International Journal of Medical Research & Health Sciences, 2018, 7(12): 141-148. (non-SCI)
